Vesting of All Employee Share Scheme

ABCAM PLC

Vesting of 'AbShare', Abcam's All Employee Share Scheme

5 November 2021, Cambridge, UK - Abcam plc ("Abcam" or "the Company") (AIM LSE: ABC; Nasdaq: ABCM), is delighted to announce that the performance conditions have been met for AbShare, the Group's all employee share scheme launched in 2018, and all awards will vest in full on Monday 8 November.

The scheme will see approximately 1.8 million shares awarded to over 1,350 employees (excluding the Executive Directors) who elected to participate in the plan, which has won multiple awards, including being voted the most innovative and creative share plan by the Global Equity Awards in 2019.

Shares under the AbShare plan were awarded at £12.19 a share, the prevailing price in November 2018. This compares with the closing price as of 4 November 2021 of £16.91.

Commenting on the news, Nick Skinner, SVP of HR, said:

"AbShare was launched in 2018 with the goal of fostering greater employee ownership across our entire global worksforce. I am delighted that as that programme vests, approximately 90% of our global team are now shareholders in the Company."

--- Ends ---

Abcam plc

+44 (0) 1223 696 000

James Staveley, VP Investor Relations

Marc Perkins, Company Secretary

Numis - Nominated Advisor & Joint Corporate Broker

+ 44 (0) 20 7260 1000

Garry Levin / Freddie Barnfield / Duncan Monteith

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam's ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).

For more information, please visit corporate.abcam.com.